动脉粥样硬化的抗炎靶点ApoB-100的研究进展  

Advances of anti-inflammation therapy targeting ApoB-100 against atherosclerosis

作　　者：郭小瑜 薛雨晨 何斌[1] 薛晓梅[1] 洪婷 尤纱纱 GUO Xiao-yu;XUE Yu-chen;HE Bin;XUE Xiao-mei;HONG Ting;YOU Sha-sha(Department of Anesthesiology and SICU,Xinhua Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200092,China)

机构地区：[1]上海交通大学医学院附属新华医院麻醉与重症医学科,上海200092

出　　处：《上海交通大学学报（医学版）》2018年第9期1104-1108,共5页Journal of Shanghai Jiao tong University:Medical Science

基　　金：国家自然科学基金(81470390);上海市教育委员会高峰高原学科建设计划(20152218);上海申康医院发展中心促进市级医院临床技能与临床创新三年行动计划(16CR3006A);上海市科学技术委员会科研计划项目(17411954700)~~

摘　　要：动脉粥样硬化是由多种因素共同作用导致的血管壁的免疫炎症性疾病,是众多心血管疾病发生的主要病理基础。目前比较公认的动脉粥样硬化发生机制是"炎症反应"学说,即低密度脂蛋白(low density lipoprotein,LDL)中所包含的载脂蛋白ApoB-100的异常增高引起的病理性炎症反应是导致动脉粥样硬化的主要因素。通过免疫疗法抑制ApoB-100导致的病理性炎症反应,有望延缓动脉粥样硬化的发生与发展。该文主要围绕ApoB-100疫苗以及其他ApoB-100抑制剂的最新进展和存在的问题进行综述。Atherosclerosis is an inflammatory disease of arterial wall caused by many factors,which is the main pathological basis of many cardiovascular diseases.Currently,"inflammatory response"theory is widely accepted as pathogenesis of atherosclerosis.Abnormal increase of apolipoprotein ApoB-100,a composition of low density lipoprotein(LDL),which causes pathological inflammation,is a major factor leading to atherosclerosis.Therefore,inhibition of ApoB-100 induced pathological inflammatory response by immunotherapy is expected to delay the development of atherosclerosis.This review focused on the recent advances of ApoB-100 vaccine and other ApoB-100 inhibitors against atherosclerosis.

关 键 词：ApoB-100 动脉粥样硬化 免疫 疫苗 抑制剂 

分 类 号：R541.4[医药卫生—心血管疾病]